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Early Th1 immunity promotes immune tolerance and
may impair graft-versus-leukemia effect after 
allogeneic hematopoietic cell transplantation
Acute graft-versus-host disease (aGvHD) is an unpre-
dictable immunological complication that affects the
skin, gut, or liver following allogeneic hematopoietic cell
transplantation (HCT). Donor Th1 cells can initiate
aGvHD after recognition of recipient alloantigens and
migration to target tissues via homing receptors.1
Paradoxically, experiments in animal models of trans-
plantation suggest that deficiency of the inflammatory
Th1 cytokine IFN-γ can exacerbate aGvHD severity and
mortality.2,3 Investigators have interpreted these results to
mean that other cell types are capable of generating
aGvHD or that loss of a protective function related to
IFN-γ was responsible for the intensified alloreactivity
observed in these animal models.
Indeed, IL-17 secreting Th17 cells can initiate aGvHD
with skin as the principal target under certain experimen-
tal conditions.4 IFN-γ also up-regulates the inhibitory
molecule, programmed cell death 1 ligand [PD-L1,
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Table 1. Characteristics of total cohort, 42 patients undergoing HLA identical sibling donor transplant using mobilized peripheral blood stem
cells.
N. of patients with characteristic, for indicated grade of aGvHD (percentage)
GvHD Univariate Multivariate
Grade 0-1 Grade 2-4*   analysis HR
Characteristic N= 11 N= 31 P (95% CI) P
Age in years
Median 54 52 0.529
Range 42-65 24-70
Sex
Male 9 (82) 16 (52) 0.080
Female 2 (18) 15 (48)
Diagnosis
AML + MDS 3 (27) 13 (42) -
CML + MPD 1 (9) 1 (3)
Lymphoid malignancy 7 (64) 17 (55)
Disease risk**
Standard 4 (36) 16 (52) 0.384
High risk 7 (64) 15 (48)
Conditioning regimen
Myeloablative 4 (36) 13 (42) 0.746 1
Reduced intensity 7 (64) 18 (58) 0.94 (0.40-2.21) 0.887
Donor / recipient sex
Female to male 1 (9) 4 (13) 1.00
Other 10 (91) 27 (87)
aGvHD prophylaxis
CSA + methotrexate 4 (36) 13 (42) 0.746
CSA + MMF 7 (64) 18 (58)
CD34+, x 106/kg 
Median 7.79 6.93 0.910
Range 4.63-10.4 3.92-10.1
CD3+, x 107/kg§
Median 32.1 34.3 0.864
Range 16.8-87.9 16.0-162
Neutrophil engraftment
Median day 18 19 0.897
Range 10-31 14-27
aGvHD target organ
None 8 (73) - -
Skin only 3 (27) 4  (13)
Gut only - 18 (58)
Multi-organ - 9  (29)
Day 100 survival†
Alive 10 (91) 30 (97) -
Dead 1   (9) 1   (3)
Engrafted sST2 (ng/mL) 
Median 16.0 22.0 0.081
Range 0.1-215 6-435
Day+30 sST2 (ng/mL)
Median 14.0            26.0 0.043 1.02 (1.01-1.02) <0.001
Range 0.1-232 6.0-521
(CD274)].5,6 Binding of PD-L1 to its receptor programmed
cell death 1 [PD1, (CD279)] on T cells leads to apoptosis
and promotes immune tolerance.7 Thus, IFN-γ seems to
have opposing functions during HCT. IFN-γ expression is
increased at sites of active aGvHD while complete Th1
deficiency intensifies aGvHD severity. Although such
findings present an apparent contradiction, it is possible
that differing migration patterns by the various cell types
or expression of effector molecules in the systemic versus
local compartments might explain the contrasting out-
comes of such studies. We tested the hypothesis that
effector T cells can be inflammatory [(mediating pro-
GvHD and graft-versus-leukemia effects (GvL)] or
inhibitory (mediating anti-GvHD/GvL effects) depending
on their expression of tissue-homing molecules on T
cells, such as cutaneous lymphocyte antigen (CLA) or the
gut-homing marker a4b7. 
Patients with hematologic malignancies undergoing 
T-cell-replete, matched-related donor (MRD) HCT were
accrued to an aGvHD biomarker study (n=42). All
patients received HLA-identical peripheral blood stem
cell grafts followed by prophylaxis with cyclosporine and
either methotrexate or mycophenolate mofetil. By
day+100, grade 2-4 or grade 3-4 aGvHD was diagnosed
clinically in 31 or 4 patients, respectively (Table 1).8
aGvHD was confirmed by biopsy in the majority (n=23). 
Flow cytometry, soluble suppression of tumorigenicity
2 (sST2), and statistical analysis are presented in the
Online Supplementary Methods.
Tissue-specific T cells were identified in blood from
healthy volunteers (n=21) or from recipients of HLA-
identical sibling donor transplants at 2 time points: neu-
trophil engraftment (n=42, median 19 days post HCT)
and at day+30 (n=37) (Online Supplementary Figure S1).
Among HCT recipients, circulating Th17 cells at engraft-
ment preferentially expressed a skin-homing (CLA+) phe-
notype (10.5% vs. 2.14%; P<0.001), while Th1 cells
demonstrated an increased frequency of gut-homing 
(a4b7+) phenotype (27.1% vs. 14.0%; P<0.001). Similar
homing patterns were seen at day+30 and among healthy
volunteers, supporting the importance of Th17 and Th1
subsets for cutaneous or gastrointestinal immunity,
respectively (data not shown). 
Among patients with grade 2-4 aGvHD (n=31), T-cell
analysis could be performed before clinical alloreactivity
in all but 3 individuals when sampling occurred during
hyperacute symptoms. Both percentage and absolute
number of circulating Th1 cells at engraftment were sig-
nificantly lower in patients developing grade 2-4 aGvHD
when compared to recipients with grade 0-1 disease,
while Th1 cell percentages were similar between healthy
volunteers and HCT recipients without alloreactivity
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T-cell subsets‡
Total CD4+ (%)
Median 61.3 59.1 0.553
Range 16.4-77.0 35.3-78.9
Total Th1 (%)
Median 18.7 6.29 0.027 0.90 (0.93-0.97) 0.004 
Range 3.16-28.8 1.18-16.9
CLA+ Th1 (%)
Median 0.78 2.78 0.001
Range 0.18-3.54 0.39-11.2
a4b7+ Th1 (%)
Median 21.2 31.5 0.021
Range 5.72-59.0 12.7-41.2
CLA-a4b7- Th1 (%)
(Conventional Th1)
Median 77.4 66.0 0.016
Range 39.5-94.1 47.3-82.9
Total Th17 (%)
Median 0.41 0.72 0.219
Range 0.05-2.13 0.06-2.46
CLA+ Th17 (%)      
Median 12.0 9.16 0.567
Range 1.08-51.6 2.34-35.9
a4b7+ Th17 (%)           
Median 14.4 13.6 0.699
Range 1.92-41.9 3.84-41.7
CLA-a4b7- Th17 (%) 
(Conventional Th17)
Median 70.2 74.9 0.122
Range 46.0-84.7 41.7-92.5
aGvHD: acute graft-versus-host disease; HR: hazard ratio; CI: confidence interval; AML: acute myelogenous leukemia; MDS: myelodysplastic syndrome; CML: chronic myeloid
leukemia; MPD: myeloproliferative disorder; CSA: cyclosporine; MMF: mycophenolate mofetil; sST2: soluble suppression of tumorigenicity 2; CLA: cutaneous lymphocyte antigen.
*Maximum grade of aGvHD during first 100 days. aGvHD occurred at a median of 37 days (range 13-93 days) after allogeneic hematopoietic cell transplantation.
**Standard risk disease is defined by acute leukemia in CR1 or 2, CML in chronic phase 1, MDS without excess blasts. All others were considered high-risk disease. §Data were
available for 38 of the 42 patients. †Causes of death included: relapse of malignancy (n=1) and infection (n=1). ‡CD4+ cells and Th subsets were analyzed at time of neutrophil
engraftment. Total CD4+ T cells were expressed as the percentage of CD3+ T cells, while total Th1 and Th17 cells were expressed as the percentage of CD4+ T cells. Skin-homing
(CLA+), gut-homing (a4b7+), and conventional (CLA–a4b7–) Th1 or Th17 subsets were expressed as a percentage of the total Th1 or Th17 population.
. 
(Table 1 and Figure 1). After adjusting for conditioning
intensity and day+30 sST2, decreased percentages of
total Th1 cells at engraftment continued to be a signifi-
cant predictor of moderate to severe aGvHD (Table 1).9
We were unable to find an association between total Th1
cells at day+30 and Th17 cells with the development of
aGvHD (Table 1 and Figure 1). The remainder of analyses
focused on Th1 subsets at engraftment.
We hypothesized that the observed decrease in Th1
cells in patients with clinical alloreactivity could repre-
sent the migration of effector cells from the systemic cir-
culation to an aGvHD target tissue. Consistent with this
idea, patients with grade 2-4 aGvHD had increased fre-
quencies of circulating skin-homing (CLA+) Th1 cells and
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Figure 1.  The development of acute graft-versus-host disease (GvHD) is associated with changes in Th1 subsets early after allogeneic hematopoietic stem
cell transplantation. The percentages or absolute numbers of total (A and B), skin-homing (CLA+) (C and D), gut-homing (a4b7+) (E and F), or conventional (CLA-
a4b7-) Th1 cells (G and H) are compared between healthy volunteers and patients with grade 0-1 or grade 2-4 acute GvHD. Box plots define the values for medi-
an, range, and 25th and 75th percentiles. Engraftment and day+30 Th1 subset frequencies are presented in graphs A, C, E, and G and absolute numbers of the
respective populations are presented in graphs B, D, F, and H. Two-tailed P values were calculated using the Mann-Whitney U test. 
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gut-homing (a4b7+) Th1 cells, but lower numbers of con-
ventional (CLA- a4b7–) Th1 cells than patients with grade
0-1 aGvHD (Table 1 and Figure 1). When analyzing
patients with isolated skin aGVHD, CLA+ Th1 cells were
increased in patients with more severe skin involvement
(stage 3-4) versus those with stage 0-2 (6.51% vs. 0.78%;
P=0.013).  After excluding individuals with skin aGvHD,
a4b7+ Th1 cells tended to be higher in patients with any
stage of gut-only aGvHD (32.8% vs. 21.8%; P=0.08). The
absolute decrease in conventional (CLA- a4b7-) Th1 cells
in the blood of patients developing aGvHD could result
from upregulation of homing-markers within this lym-
phocyte population followed by migration from the cir-
culation to a peripheral compartment, thus explaining
why the relative frequency of tissue-specific T cells in
blood changed but not the absolute numbers (Figure 1). 
Since alloimmunity can lead to both detrimental
aGvHD and beneficial GvL effects, exploratory analyses
were performed to determine whether circulating total
Th1 subsets at engraftment could impact the cumulative
incidence of malignancy relapse in patients with
MDS/AML (n=16; 7 relapses post HCT). The majority of
individuals had standard risk disease (n=13), and all
patients had less than 5% blasts prior to HCT. As sug-
gested by the aGvHD data, decreased percentages of total
Th1 cells at engraftment  predicted a lower risk of
MDS/AML relapse after adjustment for conditioning
intensity and disease risk (HR 0.84; 95%CI: 0.71-0.99;
P=0.047).  To investigate the potential inhibitory mecha-
nisms of IFN-γ on GvL in our study, we examined PD1
and PD-L1 expression on circulating CD4+ T cells and
CD14+ monocytes, respectively, between engraftment
and day +30 after HCT (Online Supplementary Figure
S2).5,10
Since cryopreserved specimens at the time of relapse
were not available, PD-L1 expression by monocytes was
used as a surrogate measure of IFN-γ effects on residual
MDS/AML cells persisting after HCT. In the 14
MDS/AML patients with accessible samples, total Th1
cells at engraftment correlated positively with both
PD1+CD4+ T cells and PD-L1+CD14+ monocytes (Figure
2). Increased PD-L1 expression by CD14+ monocytes also
predicted a greater risk for MDS/AML relapse (HR 1.11;
95%CI: 1.01-1.24; P=0.048). 
Early increases in Th1 cells were associated with
decreased alloreactivity and greater PD-L1 expression fol-
lowing HCT . Furthermore, we expanded upon the find-
ings from previous animal studies by identifying tissue-
homing subsets within this Th1 population that are criti-
cally important for either generating or preventing
aGvHD. 
Clinical manifestations of aGvHD often occur early
after engraftment and are restricted to particular tissues,
suggesting tissue-specific expression of effector mole-
cules or peripheral localization of lymphocytes are
responsible for aGvHD. Similar to our previous Treg data,
our current report supports lymphocyte tissue-trafficking
as an important factor for alloreactivity, as patients devel-
oping grade 2-4 aGvHD had increased skin-homing
(CLA+) and gut-homing (a4b7+) Th1 cells and tended to
have more cutaneous or gastrointestinal symptoms,
respectively.11,12 As opposed to lymphocyte migration
determining aGvHD, it is also plausible that conventional
(CLA-a4b7-) Th1 cells possess immunoregulatory prop-
erties.  When we analyzed Foxp3 expression, the Foxp3+
cells appeared separate and distinct from the Th1 subsets,
indicating that these IFN-γ+ lymphocytes likely were not
traditional Tregs (Online Supplementary Figure S3).  
IFN-γ induces expression of programmed death ligand 1
(PD-L1) on antigen presenting cells, which leads to apop-
tosis of PD1-expressing T cells and anergy.7 Consistent
with the idea of IFN-γ mediated immune regulation, we
have shown a very strong, positive correlation between
the percentage of total Th1 cells at engraftment with the
expression of PD1 and PD-L1 by CD4+ T cells or CD14+
monocytes, respectively. This preliminary data indicate
that early Th1 cell proliferation primarily within the
CLA-a4b7- compartment could promote peripheral toler-
ance by up-regulating the inhibitory protein PD-L1.
Although we showed a correlation between IFN-γ and
PD-L1, it is unknown whether the expression of PD-L1
on monocytes is a valid surrogate for IFN-γ effects on
AML cells or the cause for relapse, and further experi-
mentation is required. 
Some, but not all, research supports a role for Th17
cells in the generation of cutaneous aGvHD.4,13 We found
that CLA was expressed more commonly by Th17 cells
than by Th1 cells; however, the frequency of cells in
Th17 subsets did not correlate with aGvHD. These
analyses were possibly limited by the low incidence of
cutaneous alloreactivity. Strikingly, about 70% of our
MRD cohort developed aGvHD with gastrointestinal
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Figure 2. Th1 subsets correlate positively with PD1 and PDL1 expression by
CD4+ T helper cells (A) and CD14+ monocytes (B), respectively. Data were
derived from 14 patients with myelodysplastic syndrome/acute myelogenous
leukemia undergoing HLA-identical sibling donor allogeneic hematopoietic
cell transplantation. Filled circles represent patients with malignancy relapse
after transplant. Two-tailed P values were calculated using the Spearman’s
rank correlation coefficient.
A
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symptoms. Reassuringly, sST2, a validated biomarker for
aGvHD, was elevated in patients developing alloreactivi-
ty.9 The high incidence of gastrointestinal aGvHD likely
was due to early endoscopy, as previously reported.14 
Malignancy relapse and severe aGvHD are the primary
causes for early HCT failure.  Blockade of immune check-
points including CTLA-4 with ipilimumab or PD1 with
nivolumab and pembrolizumab could improve GvL, but
also may increase aGvHD.10,15 Concerns regarding aGvHD
exacerbation may have dampened enthusiasm for PD1
blockade after allogeneic HCT.15 Our data confirm pre-
clinical research that early Th1 immunity is associated
with immune tolerance and increased PD-L1 expression.
It also potentially explains the paradoxical nature of 
IFN-γ during HCT in terms of lymphocyte compartmen-
talization (i.e. inflammatory tissue-homing Th1 cells vs.
inhibitory conventional Th1 cells). If validated, these
results could identify patients with low aGvHD risk who
may benefit from therapies targeting immune check-
points to promote GvL and prevent malignancy relapse.
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